TemozolomideAn apoptosis inducer which causes arrest at the G2/M cell cycle checkpoint

Temozolomide (CAS 85622-93-1)

Temozolomide | CAS 85622-93-1 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_17, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203292, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 71ms
  • REVIEWS, PRODUCT
Synonym: 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
Application: An apoptosis inducer which causes arrest at the G2/M cell cycle checkpoint
CAS Number: 85622-93-1
Purity: ≥99%
Molecular Weight: 194.2
Molecular Formula: C6H6N6O2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Temozolomide is an antitumor, antiangiogenic compound that has been shown to work by alkylating DNA, typically through addition of a methyl group to guanine in genomic DNA. The efficacy of this compound is dependent on its ability to methylate the DNA, thus triggering apoptosis; however, some cells are able to repair this damage via the enzymes O-6-methylguanine-DNA methyltransferase (MGMT). As a consequence, temozolomide is far more efficacious in tumor cells that have silenced this repair enzyme. Research has also been conducted to determine whether MGMT inhibitors such as O-6-benzylguanine might help to increase the efficacy of temozolomide. Furthermore, temozolomide has been implicated in causing arrest at the G2/M cell cycle checkpoint, which might also play a role in its cytotoxicity.


References

1. Stevens, M.F., et al. 1984. J. Med. Chem. 27: 196-201. PMID: 6694168
2. Newlands, E.S., et al. 1997. Cancer Treat. Rev. 23: 35-61. PMID: 9189180
3. Wang, Y., et al. 1997. J. Org. Chem. 62: 7288-7294. PMID: 11671842
4. Hirose, Y., et al. 2001. Cancer Res. 61: 1957-1963. PMID: 11280752
5. Tentori, L., et al. 2002. Blood. 99: 2241-2244. PMID: 11877304
6. Kurzen, H., et al. 2003. Anticancer Drugs. 14: 515-522. PMID: 12960735
7. Günther, W., et al. 2003. Br. J. Cancer. 88: 463-469. PMID: 12569392
8. Beier, D., et al. 2008. Cancer Res. 68: 5706-5715. PMID: 18632623
9. Quinn, J.A., et al. 2009. J. Clin. Oncol. 27: 1262-1267. PMID: 19204199

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water (5 mg/ml at 25° C), DMSO (39 mg/ml at 25° C), and ethanol (<1 mg/ml at 25° C).
Storage :
Store at -20° C
Melting Point :
212° C (dec)
Boiling Point :
526.59° C at 760 mmHg (Predicted)
Density :
1.97 g/cm3 (Predicted)
Refractive Index :
n20D 1.90 (Predicted)
IC50 :
HCT-116: IC50 = 4.34 µM (human); TLX-5: IC50 = 5 µM (mouse); C6: IC50 = 34 µM (rat); PABP: IC50 = 43.45 µM (human); Tyrosine-protein kinase ABL: IC50 = >100 µM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
NJ5927050
PubChem CID :
5394
Merck Index :
14: 9139
MDL Number :
MFCD00866492
Beilstein Registry :
5547136
SMILES :
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Temozolomide  Product Citations

See how others have used Temozolomide. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 14 total

PMID: # 30899372  Guo, Z.|Wang, H.|Wei, J.|Han, L.|Li, Z.| et al. 2019. Am J Transl Res. 11: 696-708.

PMID: # 27814544  Isidori, M. et al. 2016. Environ. Pollut. 219: 275-287.

PMID: # 26971211  Ferre-Aracil, J. et al. 2016. The Science of the total environment. 556: 70-9.

PMID: # 25797272  Briest, F. et al. 2015. Oncotarget. 6: 8185-99.

PMID: # 25124055  Negreira, N. et al. 2014. Sci. Total Environ. 497-498: 68-77.

PMID: # 24667756  Negreira, N. et al. 2014. The Science of the total environment. 482-483: 389-98.

PMID: # 24148406  2013. Talanta. 116: 290-9.

PMID: # 23357749  Negreira, N. et al. 2013. J Chromatogr A. 1280: 64-74.

PMID: # 23736154  Sooman, L. et al. 2013. Cancer Chemother. Pharmacol. 72: 329-40.

PMID: # 23074197  Lee, JS. et al. 2012. Neuro-oncology. 14: 1332-45.

Citations 1 to 10 of 14 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 71ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Alonso Alonso, MM. et al. (PubMed 18089777) combined Temozolomide, a known antitumor compound, with the oncolytic adenovirus -24-RGD, to determine their efficacy against Temozolomide resistant gliomas expressing the DNA repair enzyme MGMT. Immunocompromised mice xenografted with human glioma saw a significant increase in survival when treated with Temozolomide and -24-RGD. -SCBT Publication Review
Date published: 2015-07-09
  • y_2019, m_9, d_17, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203292, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 9ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.